Building in Houston expands Eli Lilly’s United States production at a time when its competitor, Novo Nordisk, maker of ...

One of them is already a leader in the market for weight management drugs, and the other could join this field.

The struggling Danish company says it looks to reorganize, with the impact on North Carolina workers still unclear.

This Denmark-headquartered company underestimated demand for its anti-obesity treatment Wegovy when it launched in the U.S.

Novo, which has 78,400 positions globally, said about 5,000 of the job cuts will be in its native Denmark. Read more at ...

There are fears Denmark is facing a so-called “Nokia risk”. Read more at straitstimes.com. Read more at straitstimes.com.

Novo Nordisk, the maker of blockbuster weight-loss drug Wegovy, said on Wednesday it will cut 9,000 jobs in a bid to reignite ...

The Institute for Clinical and Economic Review (ICER) on Tuesday released a Draft Evidence Report assessing the comparative ...

The Danish pharmaceutical giant, which is looking to revive growth, used to be Europe's most valuable company listed on ...

Novo Nordisk will lay off 9,000 employees worldwide as part of a restructuring plan, redirecting savings to diabetes and obesity drug growth.